Trials / Unknown
UnknownNCT00309660
Treatment With Local PPARgamma Ligand in Distal Ulcerative Colitis
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (planned)
- Sponsor
- Herlev Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Treatment with PPARgamma ligands have been shown to reduces intestinal inflammation in murine models of colitis. The aim of this study was to evaluate the effect of treatment with local PPARgamma ligand (rosiglitazone) in distal ulcerative colitis.The patients are treated with rosiglitazone enema, once a day, for fourteen days. Disease activity was assessed before and after treatment by endoscopical and clinical activity score.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rosiglitazone |
Timeline
- Start date
- 2005-11-01
- Completion
- 2007-06-01
- First posted
- 2006-04-03
- Last updated
- 2006-09-21
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT00309660. Inclusion in this directory is not an endorsement.